Professor Garth Cooper
Professor Garth Cooper, professor of Biochemistry & Clinical Biochemistry, School of Biological Sciences, and Department of Medicine, Faculty of Medical and Health Sciences, is distinguished by his contributions to the molecular pathophysiology and experimental therapeutics of diabetes mellitus for which he was elected a Fellow of the Academy of Medical Sciences (UK) in 2013, based on exceptional contributions to the medical sciences.
Professor Cooper discovered amylin, the pancreatic islet β-cell hormone that constitutes islet amyloid in type-2 diabetes, and invented amylin replacement therapy (the amylin agonist, ‘pramlintide’) as a new treatment for this disease, registered by the USFDA in 2005 for the treatment of both major types of diabetes. He is also Director and Professor of Discovery & Experimental Medicine, Centre for Advanced Discovery & Experimental Therapeutics (CADET), University of Manchester, UK. His teams work in parallel in both nonclinical models and human clinical trials, applying powerful techniques aimed at understanding the molecular basis of ageing-related diseases, particularly diabetes, heart failure, and dementia.